Oruka Therapeutics, Inc. (ORKA)
ORKANASDAQ-GMBiotechnology: In Vitro & In Vivo Diagnostic Substances
$109.50
+2.44 (+2.28%) today
Closed, Nov 10, 4:00 PM ET
- Market cap
- $7.25bn
- P/E
- –
- EPS, last 4 quarters
- $-2.11
- Dividend yield
- –
- Day range
- –
- 52-week range
- $25.23 to $115.52
- Average volume
- 926.3k
- Previous close
- $107.06
Analysts
12 coveringBuy12 buy, 0 hold, 0 sell
Targets a year out average $151.73, +38.6% from here
Earnings
next estimate $-0.6700Next report
Dec 2025
+26.2%
Mar 2026
+7.7%
Jun 2026
-12.2%
Sep 2026
+7.3%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$34.10m | -$34.43m | -$36.43m | -$50.11m |
| Net income | -$30.28m | -$29.58m | -$31.82m | -$41.21m |
News
8 latest- Oruka Expects ORKA-001 52-Week Data In December; Phase 3 Start Planned For 2027 RTTNews · 14 hours ago
- Oruka’s ORKA-001 Delivers 61% Complete Skin Clearance in Phase IIb Psoriasis StudyMarketBeat · Oct 26, 2026
- Three Movers And A Catalyst: SGRY, XNCR, ORKA Gain As Acumen Nears ALTITUDE-AD Readout RTTNews · Oct 26, 2026
- Oruka's Experimental Drug Shows Strong Skin Clearance In Phase 2 Psoriasis Trial RTTNews · Oct 26, 2026
- Oruka Advances ORKA-001 Toward Phase 3 After Positive Psoriasis Data RTTNews · Oct 26, 2026
- These 2 Stocks Have Run Circles Around the Magnificent Seven This Year, and Wall Street Says There Is More Upside AheadThe Motley Fool · Oct 15, 2026
- Weekly Buzz: MESO, LLY, ANIP Win FDA Nod; KALA, HCTI Sign LOI; IMVT Halts Lupus Study RTTNews · Sep 25, 2026
- ORKA Stock Down 5% Despite Positive Week 28 Psoriasis Efficacy DataZacks · Sep 24, 2026
The company
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka's mission is to offer patients suffering from inflammatory diseases like plaque psoriasis and hidradenitis suppurativa the greatest possible freedom from their condition by achieving high rates of disease clearance with dosing as infrequently as once or twice a year.
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- orukatx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.